BR112017009552A8 - Métodos para alvejar o controle transcricional em regiões de super-realçador - Google Patents
Métodos para alvejar o controle transcricional em regiões de super-realçadorInfo
- Publication number
- BR112017009552A8 BR112017009552A8 BR112017009552A BR112017009552A BR112017009552A8 BR 112017009552 A8 BR112017009552 A8 BR 112017009552A8 BR 112017009552 A BR112017009552 A BR 112017009552A BR 112017009552 A BR112017009552 A BR 112017009552A BR 112017009552 A8 BR112017009552 A8 BR 112017009552A8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- super
- transcriptional control
- enhancer regions
- target transcriptional
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077042P | 2014-11-07 | 2014-11-07 | |
| US62/077,042 | 2014-11-07 | ||
| US201562150110P | 2015-04-20 | 2015-04-20 | |
| US62/150,110 | 2015-04-20 | ||
| PCT/US2015/059566 WO2016073913A1 (en) | 2014-11-07 | 2015-11-06 | Methods to target transcriptional control at super-enhancer regions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017009552A2 BR112017009552A2 (en) | 2018-01-02 |
| BR112017009552A8 true BR112017009552A8 (pt) | 2022-10-18 |
Family
ID=55909897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017009552A BR112017009552A8 (pt) | 2014-11-07 | 2015-11-06 | Métodos para alvejar o controle transcricional em regiões de super-realçador |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180280407A1 (https=) |
| EP (1) | EP3215135B1 (https=) |
| JP (1) | JP6689841B2 (https=) |
| KR (1) | KR20170092543A (https=) |
| CN (1) | CN107205959B (https=) |
| AU (1) | AU2015342813B2 (https=) |
| BR (1) | BR112017009552A8 (https=) |
| CA (1) | CA2965690A1 (https=) |
| IL (1) | IL251816B (https=) |
| MX (1) | MX385762B (https=) |
| RU (1) | RU2737508C2 (https=) |
| WO (1) | WO2016073913A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9901574B2 (en) | 2015-04-20 | 2018-02-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| ES2739749T3 (es) | 2015-05-18 | 2020-02-03 | Tolero Pharmaceuticals Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| WO2019113260A1 (en) * | 2017-12-05 | 2019-06-13 | The Regents Of The University Of Colorado A Body Corporate | Genomic targets of histone deacetylase inhibitors (hdaci) and methods of use thereof |
| EP3758753A1 (en) * | 2018-02-27 | 2021-01-06 | Pfizer Inc | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor |
| CN113196055B (zh) | 2018-10-15 | 2025-06-27 | 马克斯·普朗克科学促进协会 | 用于治疗疾病的化合物及其筛选方法 |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| CA3127237A1 (en) | 2019-02-08 | 2020-08-13 | Dewpoint Therapeutics, Inc. | Methods of characterizing condensate-associated characteristics of compounds and uses thereof |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| KR20220084047A (ko) | 2019-09-18 | 2022-06-21 | 듀포인트 테라퓨틱스, 인크. | 응축물 관련 특이성에 대한 스크리닝 방법 및 이의 용도 |
| US20250305055A1 (en) * | 2021-12-22 | 2025-10-02 | Cornell University | Prognostic/predictive breast cancer signature |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030026069A (ko) * | 2001-09-24 | 2003-03-31 | 주식회사 엘지생명과학 | 티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물 |
| RU2438664C2 (ru) * | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| EP2561867A1 (en) * | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
| CA2929652A1 (en) * | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| JP6930913B2 (ja) * | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法 |
-
2015
- 2015-11-06 EP EP15857385.7A patent/EP3215135B1/en active Active
- 2015-11-06 WO PCT/US2015/059566 patent/WO2016073913A1/en not_active Ceased
- 2015-11-06 AU AU2015342813A patent/AU2015342813B2/en not_active Ceased
- 2015-11-06 RU RU2017118833A patent/RU2737508C2/ru active
- 2015-11-06 CN CN201580060262.XA patent/CN107205959B/zh not_active Expired - Fee Related
- 2015-11-06 BR BR112017009552A patent/BR112017009552A8/pt not_active Application Discontinuation
- 2015-11-06 US US15/524,953 patent/US20180280407A1/en not_active Abandoned
- 2015-11-06 JP JP2017523502A patent/JP6689841B2/ja not_active Expired - Fee Related
- 2015-11-06 MX MX2017005861A patent/MX385762B/es unknown
- 2015-11-06 CA CA2965690A patent/CA2965690A1/en not_active Abandoned
- 2015-11-06 KR KR1020177013707A patent/KR20170092543A/ko not_active Ceased
-
2017
- 2017-04-20 IL IL251816A patent/IL251816B/en unknown
-
2019
- 2019-12-30 US US16/730,810 patent/US20200316084A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL251816A0 (en) | 2017-06-29 |
| JP2017533222A (ja) | 2017-11-09 |
| AU2015342813B2 (en) | 2021-04-22 |
| EP3215135A1 (en) | 2017-09-13 |
| CN107205959A (zh) | 2017-09-26 |
| RU2737508C2 (ru) | 2020-12-01 |
| JP6689841B2 (ja) | 2020-04-28 |
| MX2017005861A (es) | 2017-06-26 |
| US20180280407A1 (en) | 2018-10-04 |
| RU2017118833A (ru) | 2018-12-10 |
| BR112017009552A2 (en) | 2018-01-02 |
| WO2016073913A1 (en) | 2016-05-12 |
| KR20170092543A (ko) | 2017-08-11 |
| RU2017118833A3 (https=) | 2019-06-17 |
| CN107205959B (zh) | 2021-02-12 |
| EP3215135B1 (en) | 2020-05-13 |
| EP3215135A4 (en) | 2018-05-16 |
| IL251816B (en) | 2022-03-01 |
| CA2965690A1 (en) | 2016-05-12 |
| MX385762B (es) | 2025-03-18 |
| US20200316084A1 (en) | 2020-10-08 |
| AU2015342813A1 (en) | 2017-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX391981B (es) | Derivados de benzooxazol como inmunomoduladores. | |
| MX373187B (es) | Terapia de combinación para tratar cáncer. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX389513B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| BR112016004194A8 (pt) | compostos úteis como imunomoduladores | |
| EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
| MX2017013142A (es) | Terapia combinada para tratar cáncer. | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| MX380565B (es) | Terapias combinadas de coenzima q10 para el tratamiento de cáncer. | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MX376183B (es) | Composiciones para el tratamiento de rosacea. | |
| BR112016013116A8 (pt) | inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas | |
| EA201691570A1 (ru) | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EA201792256A1 (ru) | Соли и пролекарства 1-метил-d-триптофана | |
| BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
| BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
| MX387726B (es) | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. | |
| BR112017016333A2 (pt) | compostos anticâncer | |
| BR112014024033A8 (pt) | Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B25A | Requested transfer of rights approved |
Owner name: BOSTON BIOMEDICAL, INC. (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: SUMITOMO PHARMA ONCOLOGY, INC. (US) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B25H | Request for change of headquarter rejected |
Owner name: SUMITOMO PHARMA ONCOLOGY, INC. (US) Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870230059843 DE09/07/2023 DEVIDO AO DESPACHO PUBLICADO NA RPI 2746 DE 22/08/2023. |